Collagenase clostridium histolyticum について

Words near each other

Dictionary Lists

mini英和辞書

mini和英辞書

翻訳と辞書　辞書検索 [ 開発暫定版 ]

スポンサードリンク

Collagenase clostridium histolyticum ：ウィキペディア英語版

Collagenase clostridium histolyticum

Collagenase ''clostridium histolyticum'' is an enzyme produced by the bacterium ''Clostridium histolyticum ''that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of Dupuytren's contracture, a condition where the fingers bend towards the palm and cannot be fully straightened, and Peyronie's disease, a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. BioSpecifics Technologies developed the preparation, which is manufactured and marketed by Auxilium Pharmaceuticals as Xiaflex in the US and by Sobi as Xiapex in Europe.
==Uses==
In February 2010, the Food and Drug Administration of the United States approved Xiaflex for the treatment of Dupuytren's contracture. It is the first approved nonsurgical treatment for this condition. In a case of Dupuytren's contracture, collagen accumulates in the palmar fascia of the hands, so that the fingers cannot be straightened. A similar phenomenon occurs in Peyronie's disease, a contracture of the penis.
In February 2011, the European Commission's Committee for Medicinal Products for Human Use approved the product for the treatment of Dupuytren's contracture in adults with a palpable cord by 'properly trained' doctors.〔(''Xiapex: collagenase clostridium histolyticum'', European Medicines Agency, Undated ).Accessed: 20 March 2011.〕 Pfizer was reported to be working with Europe's national medicines regulatory bodies to launch the new treatment, hoping doctors could prescribe the treatment by late 2011.〔(''Xiapex (Collagenase Clostridium Histolyticum) Authorised In The European Union For Dupuytren's Contracture'', Medical News Today, Bexhill-on-Sea, East Sussex, 3 March 2011 ).Accessed: 19 March 2011.〕
On November 7, 2012, BioSpecifics announced Auxilium's submission of a License Application to the FDA for XIAFLEX for the potential treatment of Peyronie's disease, an excess of inelastic collagen causing penile curvature deformity. The FDA approved Xiaflex for the treatment of Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval for the treatment of Peyronie’s disease in February 2015, making it the first and only biologic therapy indicated for the treatment of Peyronie's disease.〔(Xiapex summary of product characteristics )〕 Auxilium has also reported additional trials for potential use of Xiaflex are underway for the treatment of Frozen Shoulder, Cellulite reductions and both Human and Canine Lipoma's.

抄文引用元・出典: フリー百科事典『ウィキペディア（Wikipedia）』
■ウィキペディアで「Collagenase clostridium histolyticum」の詳細全文を読む

スポンサードリンク

翻訳と辞書 : 翻訳のためのインターネットリソース